The Role of Stat5 in Estrogen Receptor-Positive Breast Cancer
スポンサーリンク
概要
- 論文の詳細を見る
- 2002-10-31
著者
-
YAMASHITA Hiroko
Department of Breast and Endocrine Surgery, Nagoya City University Medical School
-
IWASE Hirotaka
Department of Breast and Endocrine Surgery, Nagoya City University Medical School
-
Yamashita Hiroko
Department Of Surgery Ii Nagoya City University Graduate School Of Medical Sciences
-
Iwase Hirotaka
Department Of Breast And Endocrine Surgery Faculty Of Medical And Pharmaceutical Sciences Kumamoto U
-
Yamashita Hiroko
Department Of Breast And Endocrine Surgery Nagoya City University
-
Iwase Hirotaka
Department Of Breast And Endocrine Surgery Faculty Of Life Sciences Kumamoto University Graduate School Of Medical Sciences
-
IWASE Hirotaka
Department of Surgery II , Nagoya City University Graduate School of Medical Sciences
関連論文
- Clinical Usefulness of Oral Combination Chemotherapy of 5'-Deoxy-5-Fluorouridine (5'-DFUR) and Cyclophosphamide for Metastatic Breast Cancer
- Immunohistochemical Analysis on Biological Markers in Ductal Carcinoma in situ of the Breast
- Comparison of Five Different Antibodies in the Immunohistochmical Assay of Estrogen Receptor α in Human Breast Cancer
- Expression of Estrogen Receptor α Exon 5 and 7 Deletion Variant in Human Breast Cancers
- Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice
- Biweekly paclitaxel in patients with metastatic breast cancer
- Ratio of Expression of p16^ to p14^ Correlates with the Progression of Non-small Cell Lung Cancer
- Telomerase Activity Levels for Evaluating the Surgical Margin in Breast-Conserving Surgery
- Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer
- Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment
- Clinical Significance of Estrogen Receptor β in Breast Cancer
- p33^ and Estrogen Receptor (ER) α
- Alterations and Polymorphisms of the Estrogen Receptor Gene in Breast Cancer
- The Role of Stat5 in Estrogen Receptor-Positive Breast Cancer
- Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer
- Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer
- Molecular Action of the Estrogen Receptor and Hormone Dependency in Breast Cancer
- Mouse mammary gland reconstitution with extrinsic gene-transferred mammary epithelial cells in vitro and in vivo
- Clinicopathological features and treatment strategy for triple-negative breast cancer
- Estrogen receptor α gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients
- Advantage of Sentinel Lymph Node Biopsy Before Neoadjuvant Chemotherapy in Breast Cancer Treatment
- A Case Report of Paraneoplastic Neurological Syndrome Associated with Occult Breast Cancer
- Leiomyosarcoma of the Colon Presenting as Acute Suppurative Peritonitis
- Triple negative breast cancer : clinicopathological characteristics and treatment strategies
- Clinical significance of basal-like subtype in triple-negative breast cancer
- Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model
- Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor
- Midkine in plasma as a novel breast cancer marker
- Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer
- Stromal Sarcoma of the Breast with Lung Metastases Showing a Clinical Complete Response to Doxorubicin plus Ifosfamide Treatment : Report of a Case
- Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition
- Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients
- Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer
- Biweekly paclitaxel in patients with metastatic breast cancer
- Reproductive history and breast cancer risk
- Quantitative determination of insulin-like growth factor 1 receptor mRNA in formalin-fixed paraffin-embedded tissues of invasive breast cancer